Access HBsAg, Access HBsAg Confirmatory, Access HBsAg Calibrator, Access HBsAg QC
BECKMAN COULTER, INC. · Decision date Oct 17, 2025
What did the FDA decide?
FDA records P230015 as an original PMA application. The recorded decision is APRL, dated Oct 17, 2025.
FDA approval order statement
Approval for the Access HBsAg, Access HBsAg Confirmatory, Access HBsAg Calibrator, Access HBsAg QCAccess HBsAg The Access HBsAg assay is a paramagnetic particle, chemiluminescent immunoassay for the in vitro qualitative detection of hepatitis B surface antigen (HBsAg) in human pediatric (7 through 21 years) and adult serum and serum separator tubes or plasma [lithium heparin, lithium heparin separator tubes, dipotassium (K2) EDTA, tripotassium (K3) EDTA, sodium citrate, acid citrate dextrose (ACD), and citrate phosphate dextrose (CPD)] using the DxI 9000 Access Immunoassay Analyzer.The Access HBsAg assay is used for the laboratory diagnosis of acute or chronic hepatitis B virus (HBV) infection in individuals with signs and symptoms of hepatitis or at risk for hepatitis B virus infection, when used in conjunction with other serological and clinical information. The assay may also be used to screen for HBV infection in pregnant women to identify neonates who are at risk of acquiring hepatitis B during the perinatal period.The Access HBsAg assay is for use on the DxI 9000 Access Immunoassay Analyzer only.This assay has not been approved for use in the screening of blood, plasma, or tissue donors or cadaveric specimens.ACCESS HBsAg CALIBRATOR The Access HBsAg Calibrator is intended to calibrate the Access HBsAg and Access HBsAg Confirmatory assays for the in vitro qualitative detection and confirmation of hepatitis B surface antigen (HBsAg) in human serum and plasma using the DxI 9000 Access Immunoassay Analyzer.For additional information, refer to the Access HBsAg and Access HBsAg Confirmatory reagent Instructions for Use.ACCESS HBsAg QC The Access HBsAg QC is intended for monitoring system performance of the Access HBsAg and Access HBsAg Confirmatory assays. The Access HBsAg QC is for use on the DxI 9000 Access Immunoassay Analyzer.For additional information, refer to the Access HBsAg and Access HBsAg Confirmatory reagent Instructions for Use.ACCESS HBsAg CONFIRMATORYHepatitis B Virus Surface AntigenThe Access HBsAg Confirmatory assay is a paramagnetic particle, chemiluminescent immunoassay for the in vitro qualitative confirmation of the presence of hepatitis B surface antigen (HBsAg) in human pediatric (7 through 21 years) and adult serum and serum separator tubes or plasma [lithium heparin, lithium heparin separator tubes, dipotassium (K2) EDTA, tripotassium (K3) EDTA, sodium citrate, acid citrate dextrose (ACD), and citrate phosphate dextrose (CPD)] that have been found to be repeatedly reactive in the Access HBsAg assay using the DxI.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- Oct 17, 2025
Regulatory record facts
- Identifier
- P230015
- Regulatory pathway
- Premarket approval application
- Applicant
- BECKMAN COULTER, INC.
- Product code
- LOM
- Decision code
- APRL
- Decision date
- Oct 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).
- Applicant
- BECKMAN COULTER, INC.
- Product code
- LOM
- FDA device class
- 2
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230015 received
Application receipt date recorded by FDA.
P230015 · FDA decision
APRL
Timeline entries are records held by MedtechLedger for P230015. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | 510(k) clearance | Jun 4, 2026 | FDA | |
Atellica IM Hepatitis B core IgM (aHBcM)P030040/S024 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
Atellica IM Hepatitis B e Antigen (HBeAg)P090024/S013 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 17, 2025 | FDA | |
| Siemens Corp. | PMA supplement | Oct 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BECKMAN COULTER, INC.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 250 S. Kraemer Blvd., Brea, CA, 92821
Sources and methodology
- Original FDA record: P230015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


